Our research analysts offer in-depth analysis of stocks across the market-cap spectrum, albeit with a particular focus on small- and midcap companies. We strive to identify best-of-breed companies that have promising long-term outlooks with attractive, sustainable earnings growth rates.

COVID-19 has had profound influences on the U.S. economy, institutions, and lives and livelihoods of consumers. William Blair's consumer equity research team anticipates the recovery in consumer spending to continue, albeit probably at a less steep pace in coming months and with likely volatility as coronavirus cases begin to rise again.

To help sift through the rapidly changing data related to the coronavirus, the William Blair Biotechnology Research Group is publishing a twice-weekly periodical called "All the Vectors."

As the world moves to a software-centric orientation, the process by which software applications are being created and deployed is undergoing radical change.

While resale historically has been a smaller portion of the second-hand market, the more recent emergence of online resale, including consignment platforms, has helped push the market into a faster stage of growth, poised to take greater share.

P&C insurance analyst Adam Klauber believes legacy insurers should increasingly lose relevance and value over the next decade as structural impediments limit their ability to pivot toward evolving industry dynamics.

Over the last 10 years, major changes in diabetes device sales have been driven by those solutions that have demonstrated an ability to improve glycemic control (as measured by HbA1c reduction or time-in-range).

Technology analyst Jason Ader has written extensively about the rise of containers and Kubernetes in the context of next-generation, microservices-based application architectures, and now attempts to demystify the term multicloud and delve into the central role of Kubernetes in enabling enterprises to pursue a multicloud deployment model.

Technology analyst Mathew Pfau believes that digital freight matching (DFM) is a potentially massive market that has garnered a lot of attention from venture capital and private equity over the past several years.

With the robust efficacy of autologous CAR-T-cell therapies to date, the focus has shifted to commercial issues related to vein-to-vein time, manufacturing variability, shipping/chain-of-custody issues, and scalability over the long term. Allogeneic cell therapies (derived from a healthy donor) have the potential to address these issues by providing an enhanced speed to patient, availability, decreased cell variability, and streamlined manufacturing efficiencies.

This conference showcases the scientists and clinicians driving the advancements in the field of cancer immunotherapy and is designed to facilitate discussion with the audience to further elucidate underlying mechanisms of biology and promising novel therapies.

 1 2